Physician profile
Gitonga Munene
NPI 1164663829
$82,199.99
in general payments reported to CMS, 2019-2025
12 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,113 · 2020: $23K · 2021: $3,835 · 2022: $9,205 · 2023: $11K · 2024: $18K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Travel and Lodging: $6,775 · Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,807.19 |
| Travel and Lodging | $6,775.09 |
| Food and Beverage | $1,153.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $48,423.80 | 2019-2025 | Vistaseal, Ethicon, Surgiflo Hemostatic Matrix |
| Intuitive Surgical, INC. | $13,503.31 | 2020-2025 | |
| Ethicon US, LLC | $11,333.59 | 2019-2025 | Vistaseal, Surgiflo Hemostatic Matrix, Ethicon |
| Ethicon INC. | $5,005.00 | 2022-2023 | Vistaseal |
| Ethicon Endo-Surgery INC. | $3,640.00 | 2024 | Vistaseal, Ethicon, Surgiflo Hemostatic Matrix |
| Ipsen Biopharmaceuticals, INC | $90.78 | 2019 | |
| Integra Lifesciences Corporation | $47.96 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Merck Sharp & Dohme LLC | $44.58 | 2024-2025 | Keytruda |
| Abbvie INC. | $37.63 | 2023-2024 | |
| Angiodynamics, INC. | $26.72 | 2025 | Solero |
| Novartis Pharmaceuticals Corporation | $23.73 | 2024 | |
| Myriad Genetic Laboratories, INC. | $22.89 | 2024 | Precisetumor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitonga Munene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.